Immutep Limited, a clinical-stage biotechnology company specializing in advanced LAG-3 immunotherapies, has announced the completion of patient enrolment for its Phase II AIPAC-003 clinical trial. This trial aims to assess the efficacy of its investigational agent, eftilagimod alpha (“efti”), in combination with the chemotherapy drug paclitaxel, for individuals with metastatic breast cancer. The trial has […]
Sermonix Pharmaceuticals Inc., a leader in biopharmaceutical innovations, has achieved a significant milestone with the issuance of a new U.S. patent that broadens the application of its leading investigational drug, lasofoxifene. The patent, officially recorded as U.S. Patent No. 12,023,321 B2, introduces a novel method for treating estrogen receptor-positive (ER+) breast cancer that is resistant […]
In a significant update for the oncology community, G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage company specializing in cancer treatment, announced the continuation of its pivotal Phase 3 trial (PRESERVE 2). This trial is evaluating trilaciclib, in combination with gemcitabine and carboplatin, as a first-line treatment for metastatic triple negative breast cancer (mTNBC), a particularly […]
Zydus Lifesciences Limited, a leading pharmaceutical company, has achieved a significant milestone by receiving final approval from the United States Food and Drug Administration (USFDA) for its Cyclophosphamide Capsules USP, available in 25 mg and 50 mg dosages. This approval represents a major advancement in the field of oncology, as Cyclophosphamide is a key chemotherapy […]
The Menarini Group and its subsidiary, Stemline Therapeutics, Inc., have made a significant stride in breast cancer treatment with new findings from the pivotal EMERALD clinical study. These findings were recently presented at the 2023 San Antonio Breast Cancer Symposium (SABCS). The post hoc analysis of the EMERALD study demonstrated a clinically meaningful improvement in […]
Genentech, part of the Roche Group, has presented compelling results from the Phase III INAVO120 study, evaluating the effectiveness of inavolisib in combination with palbociclib (Ibrance) and fulvestrant for treating a specific group of breast cancer patients. The study focuses on individuals with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer. […]
Exai Bio, a leader in healthcare innovation, announced groundbreaking data showcasing the efficacy of its novel RNA-based and AI-driven liquid biopsy platform in detecting breast cancer at its earliest stages. The platform’s precision in identifying small tumors, including ductal carcinoma in situ (DCIS), using a standard blood sample, marks a significant advancement in cancer screening. […]
Roche, a global leader in pharmaceuticals, announced positive results from its Phase III INAVO120 study, testing the investigational therapy inavolisib in combination with palbociclib (Ibrance) and fulvestrant. This study targeted patients with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer. The trial met its primary endpoint, showing a significant improvement in […]
In a notable development in the field of oncology, the US Food and Drug Administration (FDA) has approved AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) for treating adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer. This approval is especially significant for patients with specific biomarker alterations (PIK3CA, AKT1, or […]
In a significant advancement for cancer treatment, the European Commission (EC) has approved Gilead Sciences’ Trodelvy (sacituzumab govitecan) for the treatment of adult patients suffering from unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have undergone endocrine-based therapy, and at least two more systemic therapies in the advanced phase. This medication is now […]
